Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
mergers and acquisitions
Biotech
Merck made $3B offer for MoonLake—and could revive interest: FT
Merck reportedly offered more than $3 billion to buy MoonLake Immunotherapeutics to add an inflammatory disease prospect to its late-phase pipeline.
Nick Paul Taylor
Jun 3, 2025 9:25am
Lilly lands next-gen pain asset in $1B SiteOne acquisition
May 27, 2025 11:30am
Sanofi inks $470M Vigil buyout to snag Alzheimer's prospect
May 22, 2025 4:49am
Regeneron’s $256M bid wins 23andMe bankruptcy auction
May 19, 2025 10:37am
BioMarin inks $270M Inozyme buyout, bagging phase 3 prospect
May 16, 2025 8:46am
Activist investor fails to derail Alumis' Acelyrin merger
May 14, 2025 7:45am
